Malleswar Kollu
Keine laufenden Positionen mehr
Profil
Malleswar Kollu is the founder of Sannova Analytical, Inc. which was founded in 2006.
Ehemalige bekannte Positionen von Malleswar Kollu
| Unternehmen | Position | Ende |
|---|---|---|
Sannova Analytical, Inc.
 Sannova Analytical, Inc. Miscellaneous Commercial ServicesCommercial Services Sannova Analytical, Inc. is a contract research organization that provides bioanalytical and chemistry manufacturing and controls testing services to biopharmaceutical and biotech companies for both small and large molecules. The company is based in Somerset, NJ and was founded in 2006 by Venkat Reddy, Geeta Vidiyala, and Malleswar Kollu. Sannova is known for its consistently low variability data, quick turnaround times, and over 300 validated methods. The company has completed over 1,200 clinical trials and has maintained an impeccable inspection record with the FDA and its sponsors. Sannova is considered a trusted and quality-focused partner in drug development by customers with a strong track record of regulatory compliance. Jason Apter has been the CEO of the company since 2022. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Sannova Analytical, Inc.
Sannova Analytical, Inc. Miscellaneous Commercial ServicesCommercial Services Sannova Analytical, Inc. is a contract research organization that provides bioanalytical and chemistry manufacturing and controls testing services to biopharmaceutical and biotech companies for both small and large molecules. The company is based in Somerset, NJ and was founded in 2006 by Venkat Reddy, Geeta Vidiyala, and Malleswar Kollu. Sannova is known for its consistently low variability data, quick turnaround times, and over 300 validated methods. The company has completed over 1,200 clinical trials and has maintained an impeccable inspection record with the FDA and its sponsors. Sannova is considered a trusted and quality-focused partner in drug development by customers with a strong track record of regulatory compliance. Jason Apter has been the CEO of the company since 2022. | Commercial Services |
